Figure 3: A vaccine was prepared from the standardized allogeneic and syngeneic cells administered with or without the TLR7/8 agonist, resiquimod, injected 3 times a week on Mondays, Wednesdays and Fridays. Average values of tumor growth as a function of time post-implantation for the different treatment groups.